
Kezar Life Sciences KZR
$ 6.1
-4.69%
Quarterly report 2024-Q3
added 11-12-2024
Country |
![]() |
IPO year |
2018 |
Industry |
Biotechnology |
Stock Exchange |
NASDAQ GLOBAL |
CEO |
Mr. John Fowler |
Employees in the company |
40 |
Shares |
72.6 M |
Market Cap[1] |
$ 443 M |
EBITDA (LTM) |
$ -93.4 M |
P/E (LTM) |
- |
P/S (LTM) |
- |
EPS (LTM) |
- |
Other stocks of industry "Biotechnology"
References
- Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.